 phase II evalu carboplatin chip advanc transit cell carcinoma urothelium eastern cooper oncolog group total patient metastat transit cell carcinoma system therapi random phase II evalu carboplatin cis-dichloro-transdihydroxy-bis-isopropylamin platinum IV chip day evalu patient measur diseas respons rate confid interv carboplatin confid interv chip patient evalu measur metastas carboplatin chip recipi respons median surviv evalu patient month month carboplatin month chip recipi independ factor prognost surviv perform statu versu liver metastas prior radiat therapi recent weight loss multivari analysi perform statu liver metastas predict surviv total patient carboplatin chip sever life-threaten myelosuppress respons rate carboplatin chip modest characterist agent